Market Intelligence, Clinical Progress, and High-Purity Reagents for GPER1-Targeted Oncology, Metabolic, and Cardiovascular Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GPER1 (GPR30) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GPER1 N-Terminal ECD Protein (HEK293 expressed, >95% purity, Endotoxin <1EU/ug, Sequence Verified) | View GPER1 Products |
| Gene Delivery | GPER1 Lentivirus Premade Particles (Full-length ORF NM_001505, >10^8 TU/mL, preserves native conformation) | View GPER1 Products |
| Gene Delivery | GPER1 Promise-ORF Clone (Codon-optimized, sequence verified by NGS, suitable for transient transfection) | View GPER1 Products |
| Benchmark Ab | Anti-GPER1 Recombinant Antibody (Reference sequence for expression validation) | View GPER1 Products |
| Validator | GPER1 siRNA Set (3 unique sequences, HPLC purified, endotoxin controlled) | View GPER1 Products |
| Related Target | ESR1 (ERα) – Selectivity counter-screen; distinguish GPER1-specific from classical estrogen receptor activity | View ESR1 Products |
| Related Target | ESR2 (ERβ) – Off-target binding assessment for dual-selective compound profiling | View ESR2 Products |
| Related Target | EGFR – Pathway crosstalk analysis (GPER1-mediated EGFR transactivation assays) | View EGFR Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformational Integrity (Full-length folding required for functional assays) | Lentivirus Particles for Stable Cell Lines – Native glycosylation and membrane insertion verified by Flow Cytometry; no detergent solubilization artifacts. |
| Cross-Species Translation (Mouse/Cyno models for preclinical efficacy) | Human/Mouse/Rat Ortholog ORF Available – Sequence identity verified; suitable for species-specific compound selectivity testing. |
| Selectivity vs Classical ERs (Avoiding ERα/ERβ cross-reactivity) | Receptor Panel Strategy – ESR1 and ESR2 ORF clones available for parallel transfection and competitive binding assays. |
| Knockdown Specificity Controls (Confirming on-target pharmacology) | GPER1 siRNA Validation Set – Gene-specific silencing validated at mRNA level; eliminates off-target assay artifacts. |
| Functional Signaling Readouts (Calcium flux, cAMP, ERK phosphorylation) | High-Expression Stable Lines – Lentivirus generates >95% transduction efficiency in HEK293 cells; suitable for FLIPR and BRET assays. |
Global Clinical Landscape & Future Outlook
GPER1 (GPR30) represents a non-classical estrogen receptor with rapid, non-genomic signaling kinetics. The therapeutic landscape is currently dominated by small-molecule modulators, anchored by well-characterized tool compounds such as the agonist G-1 and antagonist G-15. As the field differentiates from classical ER-targeted endocrine therapies, GPER1-selective ligands are advancing for indications where rapid membrane-initiated steroid signaling is pathogenic, including hormone-resistant breast cancer, renal fibrosis, and cardiovascular disease. Notably, the missense mutation rs11544331 (Tyr139Ala) in GPER1 has been linked to altered signaling and may contribute to drug resistance, highlighting the need for mutant-selective assay tools. The next wave of R&D is targeting biased allosteric modulators and combinatorial regimens with CDK4/6 or immune checkpoint inhibitors, necessitating precise receptor-selectivity assays that discriminate GPER1 activity from classical ESR1/ESR2 signaling.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Modulators (Agonists/Antagonists) | Academic consortia, Preclinical biotechs | Breast Cancer, TNBC, Renal Fibrosis, Cardioprotection | Selectivity Panel (GPER1 vs ESR1/ESR2); Need mutant vs WT proteins |
| Allosteric Modulator | Emerging Biotech | Cardiovascular Disease | Conformational Selectivity Panel (Need GPER1 vs ESR1/ESR2 cell lines) |
| Biologic (Peptide/Protein) | Early Discovery | Metabolic Disorders | Internalization Assay (Requires full-length GPCR presentation) |
| Combination Therapy | Oncology Institutes | Hormone-Resistant Cancers | Pathway Crosstalk Analysis (GPER1-EGFR co-expression systems) |
Live GPER1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly: